A 61-year-old woman with an abnormal radiograph shadow in her anterior mediastinum was admitted to our hospital and underwent an extended thymectomy. The pathological diagnosis of the tumor was a non-papillary adenocarcinoma of the thymus in pathological stage IV b using the Masaoka classification owing to mediastinal lymph node metastasis. We found parasternal lymph node metastases 5 months after her first operation, and subsequently, she underwent surgery and adjuvant radiotherapy. We found systemic lymph node metastases and metastatic lesions in distant organs, including her lungs, brain, and kidney 27 months after her first operation. Systemic chemotherapy, such as carboplatin plus paclitaxel and an ADOC regimen were not very effective, so we performed immunohistochemical staining of the primary thymic adenocarcinoma. The levels of both thymidylate synthase and dihydropyrimidine dehydrogenase were low; therefore, we started S-1 100mg/body (2 weeks of administration, 1 week of withdrawal)31 months after her first operation. She entered complete remission 6 months after the initiation of S-1. We surgically resected her solitary lung metastasis 13 months after initiation of S-1, and then continued the S-1 treatment. There was no recurrence for more than 2 years after the lung surgery. We believe that when the expression levels of thymidylate synthase or dihydropyrimidine dehydrogenase are low in cases of recurrent thymic adenocarcinoma, S-1 may be able to induce an effective response.
Download full-text PDF |
Source |
---|
Integr Biol (Camb)
January 2025
Manipal Academy of Higher Education (MAHE), Manipal 576104, Karnataka, India.
The role of GTF2I (General Transcription Factor2I) alteration has already been reported in thymic cancer as a valuable biomarker. However, the association of GTF2I mutation with renal cancer for prognosis of immunotherapy is not yet examined. The biologic and oncologic significance of GTF2I in renal cancer was examined at multiomics level such as mutation, copy number alteration, structural variants.
View Article and Find Full Text PDFSoft Matter
December 2024
Department of Chemistry, Birla Institute of Technology & Science (BITS) Pilani, Hyderabad Campus, Hyderabad, Telangana 500078, India.
J Cardiothorac Surg
November 2024
Department of Cardiothoracic Surgery, Dehong People's Hospital, Affiliated Dehong Hospital of Kun Ming Medical University, No.13, Yonghan Street, Dehong, Yunnan, 678400, China.
Background: With the continuous development of minimally invasive thoracic surgery, thoracoscopic thymectomy has become a routine operation. This method, now widely recognized, better protects lung function, reduces intraoperative blood loss and pain, and shortens postoperative hospital stay. We now introduce a standardized right thoracic incision for thoracoscopic thymic tumor resection, which has achieved favorable clinical outcomes.
View Article and Find Full Text PDFJ Thorac Oncol
November 2024
Royal Prince Alfred Hospital, NSW Health Pathology, Camperdown, New South Wales, Australia.
Introduction: With the implementation of low-dose computed tomography screening, multiple pulmonary tumor nodules are diagnosed with increasing frequency and the selection of surgical treatments versus systemic therapies has become challenging on a daily basis in clinical practice. In the presence of multiple carcinomas, especially adenocarcinomas, pathologically determined to be of pulmonary origin, the distinction between separate primary lung carcinomas (SPLCs) and intrapulmonary metastases (IPMs) is important for staging, management, and prognostication.
Methods: We systemically reviewed various means that aid in the differentiation between SPLCs and IPMs explored by histopathologic evaluation and molecular profiling, the latter includes DNA microsatellite analysis, array comparative genomic hybridization, TP53 and oncogenic driver mutation testing and, more recently, with promising effectiveness, next-generation sequencing comprising small- or large-scale multi-gene panels.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!